A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: A University of Colorado Cancer Center study

P. A. Bunn, Karen Kelly

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

This phase I study was designed to determine the maximal tolerated doses of carboplatin and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), as well as the safety and efficacy of these agents, in patients with advanced, nonresectable stages IIIB and IV non-small cell lung cancer. Paclitaxel was given as a 3-hour intravenous infusion followed by a 30-minute infusion of carboplatin. Patients were assigned to one of seven treatment groups in which paclitaxel and carboplatin were given in doses ranging from 135 to 225 mg/m2 and from 250 to 400 mg/m2, respectively. Overall, the two-drug combination has been well tolerated. The major dose- limiting toxicity has not been reached but will likely be neutropenia. There appears to be a dose-response relationship: two partial responses (12%) were observed among 17 patients assigned to the lower-dose groups, whereas six (50%) of 12 evaluable patients in the higher-dose groups achieved partial responses. The maximal tolerated doses have not been reached yet, and will be at least 200 mg/m2 for paclitaxel and 400 mg/m2 for carboplatin.

Original languageEnglish (US)
Pages (from-to)2-6
Number of pages5
JournalSeminars in Oncology
Volume22
Issue number4 SUPPL. 9
StatePublished - 1995
Externally publishedYes

Fingerprint

Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Maximum Tolerated Dose
Neoplasms
Proxy
Drug Combinations
Neutropenia
Intravenous Infusions
Safety

ASJC Scopus subject areas

  • Oncology

Cite this

A phase I study of carboplatin and paclitaxel in non-small cell lung cancer : A University of Colorado Cancer Center study. / Bunn, P. A.; Kelly, Karen.

In: Seminars in Oncology, Vol. 22, No. 4 SUPPL. 9, 1995, p. 2-6.

Research output: Contribution to journalArticle

@article{9207fd43e7ec4844a06b5032e28f7946,
title = "A phase I study of carboplatin and paclitaxel in non-small cell lung cancer: A University of Colorado Cancer Center study",
abstract = "This phase I study was designed to determine the maximal tolerated doses of carboplatin and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), as well as the safety and efficacy of these agents, in patients with advanced, nonresectable stages IIIB and IV non-small cell lung cancer. Paclitaxel was given as a 3-hour intravenous infusion followed by a 30-minute infusion of carboplatin. Patients were assigned to one of seven treatment groups in which paclitaxel and carboplatin were given in doses ranging from 135 to 225 mg/m2 and from 250 to 400 mg/m2, respectively. Overall, the two-drug combination has been well tolerated. The major dose- limiting toxicity has not been reached but will likely be neutropenia. There appears to be a dose-response relationship: two partial responses (12{\%}) were observed among 17 patients assigned to the lower-dose groups, whereas six (50{\%}) of 12 evaluable patients in the higher-dose groups achieved partial responses. The maximal tolerated doses have not been reached yet, and will be at least 200 mg/m2 for paclitaxel and 400 mg/m2 for carboplatin.",
author = "Bunn, {P. A.} and Karen Kelly",
year = "1995",
language = "English (US)",
volume = "22",
pages = "2--6",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "4 SUPPL. 9",

}

TY - JOUR

T1 - A phase I study of carboplatin and paclitaxel in non-small cell lung cancer

T2 - A University of Colorado Cancer Center study

AU - Bunn, P. A.

AU - Kelly, Karen

PY - 1995

Y1 - 1995

N2 - This phase I study was designed to determine the maximal tolerated doses of carboplatin and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), as well as the safety and efficacy of these agents, in patients with advanced, nonresectable stages IIIB and IV non-small cell lung cancer. Paclitaxel was given as a 3-hour intravenous infusion followed by a 30-minute infusion of carboplatin. Patients were assigned to one of seven treatment groups in which paclitaxel and carboplatin were given in doses ranging from 135 to 225 mg/m2 and from 250 to 400 mg/m2, respectively. Overall, the two-drug combination has been well tolerated. The major dose- limiting toxicity has not been reached but will likely be neutropenia. There appears to be a dose-response relationship: two partial responses (12%) were observed among 17 patients assigned to the lower-dose groups, whereas six (50%) of 12 evaluable patients in the higher-dose groups achieved partial responses. The maximal tolerated doses have not been reached yet, and will be at least 200 mg/m2 for paclitaxel and 400 mg/m2 for carboplatin.

AB - This phase I study was designed to determine the maximal tolerated doses of carboplatin and paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), as well as the safety and efficacy of these agents, in patients with advanced, nonresectable stages IIIB and IV non-small cell lung cancer. Paclitaxel was given as a 3-hour intravenous infusion followed by a 30-minute infusion of carboplatin. Patients were assigned to one of seven treatment groups in which paclitaxel and carboplatin were given in doses ranging from 135 to 225 mg/m2 and from 250 to 400 mg/m2, respectively. Overall, the two-drug combination has been well tolerated. The major dose- limiting toxicity has not been reached but will likely be neutropenia. There appears to be a dose-response relationship: two partial responses (12%) were observed among 17 patients assigned to the lower-dose groups, whereas six (50%) of 12 evaluable patients in the higher-dose groups achieved partial responses. The maximal tolerated doses have not been reached yet, and will be at least 200 mg/m2 for paclitaxel and 400 mg/m2 for carboplatin.

UR - http://www.scopus.com/inward/record.url?scp=0029027922&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029027922&partnerID=8YFLogxK

M3 - Article

C2 - 7644924

AN - SCOPUS:0029027922

VL - 22

SP - 2

EP - 6

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 4 SUPPL. 9

ER -